Form 4: Ocular Therapeutix CSO Executes Tax-Related Stock Sale

Chief Strategy Officer Sanjay Nayak sold 1,858 shares of Ocular Therapeutix to satisfy tax withholding obligations.

Summary

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc., sold 1,858 shares of common stock.
• The transaction occurred on May 26, 2026, at a weighted average price of $8.20 per share.
• The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units.
• Following the transaction, the reporting person retains beneficial ownership of 328,795 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was a mandatory, non-discretionary action to satisfy tax obligations rather than a signal of management sentiment.

Positives

• The sale was non-discretionary and executed pursuant to a pre-existing Rule 10b5-1 trading plan.

Negatives

• Reduction in direct equity holdings by a key executive.

Risks

• None identified; the transaction was a routine tax-related sell-to-cover event.

Future Outlook

No forward-looking guidance provided in this filing.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that this is a standard administrative transaction common in the biotechnology sector, where executives frequently utilize Rule 10b5-1 plans to manage tax liabilities associated with equity compensation vesting.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for tax-related sell-to-cover transactions is a standard corporate governance practice among U.S. publicly traded biotech firms.
• The transaction size is immaterial relative to the total outstanding shares of Ocular Therapeutix.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and non-discretionary.

Next Steps

• None

Key Dates

Keywords

Ocular Therapeutix, OCUL, Insider Trading, Form 4, Sanjay Nayak, Equity Vesting